Crossmark

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Crossref DOI link: https://doi.org/10.1186/s40425-018-0474-z

Published Online: 2018-12-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jensen, Christina https://orcid.org/0000-0002-3485-7307
Madsen, Daniel Hargbøl

Hansen, Morten

Schmidt, Henrik

Svane, Inge Marie

Karsdal, Morten Asser

Willumsen, Nicholas
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 27 July 2018

Accepted: 6 December 2018

First Online: 19 December 2018

Ethics approval and consent to participate

: The study was approved by the Ethics Committee for The Capital Region of Denmark (H-2-2012-058) in compliance with the Helsinki Declaration of 1975. Informed consent was obtained from all individual participants included in the study.

: Not applicable.

: MAK and NW are employed at Nordic Bioscience A/S, which is a company involved in discovery and development of biochemical biomarkers. MAK owns stocks at Nordic Bioscience.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below